Depression and schizophrenia

David Castle & Peter Bosanac

SUMMARY
Depressive symptoms commonly occur in schizophrenia and have a significant impact on the distress and burden of the illness. Yet they are often overlooked, inadequately characterised by current classification systems and not consistently integrated into treatment. We discuss nosology, practical and clinical implications of symptom differentiation, and the role of causation and confounding factors, including iatrogenic, as targets for therapeutic intervention. The evidence base for psychosocial and psychotropic management is reviewed, with recommendations for the treatment of established syndromal depression in people with schizophrenia.

DECLARATION OF INTEREST
D.C. has received: grant monies from Eli Lilly, Janssen-Cilag, Roche, Allergan, Bristol-Myers Squibb, Pfizer, Lundbeck, AstraZeneca and Hospira; travel support and honoraria for talks and consultancy from Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Lundbeck, Janssen-Cilag, Pfizer, Organon, Sanofi-Aventis, Wyeth and Hospira; and is an advisory board member for Lundbeck, Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Wyeth, Pfizer and Janssen-Cilag, and in the past for Schering-Plough. P.B. has received financial support for investigator-initiated studies from AstraZeneca, and travel support from AstraZeneca, Eli Lilly and Janssen-Cilag.

Depression frequently co-occurs with schizophrenia, yet in clinical practice it is often missed. This is partly because schizophrenia has at its core a disturbance of affect which is often associated with difficulty in expressing internal emotion. In addition, the restrictive nature of the DSM diagnostic criteria forces researchers into a situation of making a ‘diagnosis’ of a comorbid mood disorder only when all the criteria are fulfilled. For example, a diagnosis of major depressive episode in DSM-IV-TR requires at least 2 weeks of unrelenting low mood or loss of interest, plus a stipulated array of other symptoms (American Psychiatric Association 2000). If a full syndromic definition is applied, the estimated modal rate of major depression in schizophrenia is 25% (Siris 2000). Moreover, there is an overlap of the symptom dimensions of schizophrenia, which include positive, negative, depressive, manic and disorganised, and in turn the merging of affective and non-affective diagnoses without a point of rarity between (Upthegrove 2009). In reality, many patients with schizophrenia express ‘lesser’ forms of depression, not necessarily meeting diagnostic criteria but still carrying significant distress and burden for them. Such individuals have been little studied, making clinicians rely on data from a relatively unrepresentative group of patients who fulfill DSM criteria for a full mood disorder in the context of schizophrenia.

Another nosological difficulty is the problem of how DSM deals (or does not deal) with schizoaffective disorder. Originally described by Kasanin (1933), schizoaffective disorder has been a headache for DSM committees for decades. Indeed, it was the only major disorder in DSM-III (American Psychiatric Association 1980) that did not have a set of operationalised diagnostic criteria. When DSM-III-R introduced such criteria in 1987 (American Psychiatric Association 1987), it adopted a very restrictive set. This approach has been continued in subsequent iterations of the DSM, and DSM-IV-TR requires a full affective syndrome (major depressive, manic or mixed episode), frank positive symptoms (criterion A symptoms for schizophrenia) and psychotic symptoms in the absence of mood disorder. The drafts of DSM-5 show consideration being given to another restriction, that mood symptoms are present for at least 30% of the lifetime duration of the illness (Faraone 1996). None of this is helpful to clinicians, who more often than not ignore these restrictive rubrics and resort to the schizoaffective label as a useful ‘hold-all’ that carries less stigma than schizophrenia and allows the use of a more symptom-based therapeutic approach (of which more below).

Causality and confounding
Opinions on the link between depression and schizophrenia variously describe depression as intrinsic to the illness, an effect of antipsychotic medication, an expression of negative symptoms of the illness, and a psychological response to and appraisal of psychosis (Upthegrove 2009). Building on this heuristic perspective, Box 1 lists some of the factors that are associated with both schizophrenia and depression. These could equally be considered causal or confounding factors,
but for the clinician should provide targets for therapeutic interventions. Indeed, some of these factors can be driven by multiple other influences, reinforcing them and exacerbating the depression. For example, alcohol and other substance misuse is common among people with schizophrenia (Margolese 2004), in part at least because of ‘negative affect’ that includes depression (Dixon 1991). A number of these substances lead to worsening depression and thus further substance misuse, setting up and perpetuating a vicious cycle. The substance misuse itself thus becomes an important therapeutic target in dealing with the depression, and vice versa (Lybrand 2009).

Another important consideration is potential iatrogenic causes of depression in schizophrenia. A number of medications used for the physical health problems that often bedevil people with schizophrenia can themselves carry a risk of depression. More common is that some antipsychotics worsen depression (Lewander 1994). This is perhaps particularly true of the older ‘typical’ antipsychotics, albeit that studies that have looked specifically at the question of whether agents such as haloperidol ‘cause’ depression have been equivocal. Again, clinicians will be aware that some patients on medications such as haloperidol report a lowering of mood, which is ameliorated when the agent is switched to one of the newer ‘atypical’ antipsychotics. The exact mechanism here is unclear but could be a result of removal of a ‘tight’ and specific dopamine D₂-binding agent, resulting in direct effects on mood or secondary effects via enhanced clarity of cognition and/or amelioration of extrapyramidal side-effects. Whether the atypical agents are themselves antidepressive is another matter (see below).

**Differentiating depression from psychotic symptoms**

Depressive symptoms have been found to be prominent in the prodromal phase of psychosis, and worse in people who subsequently make the transition to the first episode of schizophrenia (Upthegrove 2009). Upthegrove and colleagues (2010) demonstrated that depression can be seen in the vast majority of patients with first-episode psychosis as well as over the later course of the illness (prodrome, acute phase and long-term follow-up). Moreover, their study also found that depression in the prodromal phase was the most significant predictor of future depression and self-harm.

As alluded to earlier, one of the problems of depression in schizophrenia is that symptoms of each might be mistaken for the other. This is particularly apposite when differentiating depressive symptoms from negative symptoms of schizophrenia. Indeed, Carpenter and colleagues (1988) have pointed out the importance of being aware that observed negative symptoms may be ‘secondary’, as opposed to the primary, core negative symptoms of apathetic withdrawal, restriction of affect and paucity of thought (Table 1). Thus, negative-like symptoms can be caused by typical antipsychotics (so-called neuroleptic-induced deficit syndrome; Lewander

### BOX 1 Factors associated with both schizophrenia and depression

- Social isolation
- Loss
- Unemployment
- Psychosocial stress
- Financial difficulties
- Adverse life events
- Stigma
- Alcohol misuse
- Illicit substance use
- Adverse life events
- Stigma
- Alcohol misuse
- Illicit substance use

### Table 1 Causes and treatment of negative symptoms in schizophrenia

<table>
<thead>
<tr>
<th>Symptom cause</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>The deficit syndrome (primary negative symptoms)</td>
<td>Clozapine, selective serotonin reuptake inhibitors, social skills training, cognitive remediation</td>
</tr>
<tr>
<td>Other factors (secondary, negative-like symptoms)</td>
<td></td>
</tr>
<tr>
<td>Other symptoms of schizophrenia, e.g. persecutory delusions that lead to social withdrawal</td>
<td>Social skills training, cognitive remediation</td>
</tr>
<tr>
<td>Depression</td>
<td>Medication, psychological interventions, e.g. supportive psychotherapy, cognitive–behavioural therapy</td>
</tr>
<tr>
<td>Antipsychotic medication that restricts affect or has extrapyramidal side-effects such as akinesia</td>
<td>Change medication</td>
</tr>
<tr>
<td>General medical conditions such as Parkinson’s disease</td>
<td>Treatment of the concurrent medical condition</td>
</tr>
<tr>
<td>Environmental factors or poor stimulation that lead to impaired motivation</td>
<td>Social skills training, cognitive remediation</td>
</tr>
</tbody>
</table>
1994), by positive symptoms and, pertinent to this discourse, by depression (and, for that matter, anxiety). This distinction is vital as it has profound clinical implications. For example, primary negative symptoms are strongly associated with disability in vocational and other domains, and are notoriously difficult to treat: possibly only clozapine (Essali 2009) and low-dose amisulpride (Storosum 2002) have reasonably consistent effects. On the other hand, negative-like symptoms secondary to typical antipsychotics may be alleviated either by a dose reduction or by switching to an atypical agent; such symptoms secondary to positive symptoms may require a different strategy; and depression warrants treatment in its own right, as detailed below.

**Low mood and blunted affect**

In clinical practice, a number of pointers can help to distinguish depression from negative symptoms. It should be noted that the usual reliance on patients with depression expressing low mood can break down in those with schizophrenia, as they might find it difficult to express how they ‘feel inside’. Perhaps a more useful question is that related to interest in things around them. In depression, individuals usually describe a clear shift from their usual level of interest and also regret or even anguish that they have lost their interests. In contrast, people with negative-symptom schizophrenia mostly talk of interests in a bland and affectless manner, and this tends to be their enduring long-term pattern of relating to the world around them. Eliciting feelings of guilt, hopelessness and suicidality can also help differentiate depression as well as informing risk assessment.

**Melancholic features**

Other useful indicators of depression include melancholic features such as poor sleep and appetite change. One needs to be aware that people with schizophrenia often have perturbed sleep–wake cycles (e.g. staying up late at night and sleeping during the day) and that some antipsychotics can cause sedation, appetite stimulation and weight gain.

**Rating scales**

All these factors make established depression rating scales of limited use in schizophrenia. Nevertheless, two scales warrant special mention. First, the Schedule for the Deficit Syndrome (Kirkpatrick 1989) seeks specifically to differentiate primary from secondary depressive symptoms. It comprises six items and includes both interview questions and observational items.

Second, and perhaps of more obvious clinical utility, is the Calgary Depression Scale for Schizophrenia (CDSS; Addington 1990), which was designed specifically to measure depression in people with schizophrenia. This scale is helpful in complementing clinical assessment in differentiating depression from negative symptoms and medication effects in schizophrenia (Upthegrove 2009). There is an emphasis on features such as anhedonia and guilt, and it includes two melancholic items and one suicide item. Each item is scored 0–3, and a cut-off score of 7 is indicative of clinically relevant depression. Box 2 shows the main domains assessed.

**Management**

In a patient with schizophrenia who presents with depressive symptoms, it is important to investigate organic factors such as substance misuse and endocrine and other medical problems which might be causal or at least contributory. Often people with schizophrenia have medical problems that are not fully investigated or treated, and depression may be a signal of factors such as thyroid dysfunction or cancer. As outlined earlier, it is also important to ask about prescribed medications, as these may cause depressive symptoms.

Risk assessment is critical in all cases, because depression is associated with suicidality and it is well known that suicide is a leading cause of death among individuals with schizophrenia. Although self-harm is common in all phases of first-episode psychosis, it is most likely in the pretreatment phase (the period of untreated psychosis) (Barrett 2010; Upthegrove 2010). Other risks, such as self-neglect, also need to be explored, as many people with schizophrenia are socially isolated and thus do not have significant others caring for or monitoring them.

**Psychosocial parameters**

As with any patient with depression, assessment and management of broader psychosocial parameters must be part of a comprehensive management plan. In individuals with schizophrenia, where
social dislocation, estrangement from family, lack of employment, poor housing and low income are the norm rather than the exception, such strategies are even more important. People with schizophrenia may also need help coming to terms with their illness and dealing with the stigma it carries. Demoralisation can be part and parcel of the picture and needs particular attention.

Despite a massive literature on the role of psychological therapies such as cognitive–behavioural therapy and interpersonal psychotherapy in depression, and an emerging literature on application of such interventions for people with schizophrenia (targeting positive psychotic symptoms primarily), there is a dearth of methodologically robust studies reporting the efficacy of psychological treatments for depression in schizophrenia. Most studies have assessed depression as a secondary or tertiary outcome measure and have not employed well-validated mood rating scales. Studies that have reported mood change with psychological treatments in schizophrenia have generally reported favourable trends. For example, in a meta-analysis including 1297 patients with schizophrenia, Pilling et al (2002) found that cognitive–behavioural therapy was associated with beneficial effects for psychotic symptoms and for depression, and that these effects endured over the 18-month follow-up. Thus, this is a promising area, but one that needs further study, using schizophrenia samples with depression (to enhance power to detect change) and/or specifically addressing depressed mood in patients with schizophrenia.

Pharmacological aspects

The international clinical practice guidelines for early psychosis (International Early Psychosis Association Writing Group 2005) endorse the use of the minimum effective dose of second-generation (atypical) antipsychotics in preference to first-generation (typical) antipsychotics, in tandem with ‘phase-specific’ treatment of early psychosis. These guidelines also recommend that treatment be offered for depressive syndromes in young people in an ‘at risk’ (for early psychosis) mental state, who are actively seeking treatment and who are distressed or disabled as a consequence of their symptoms. Although the guidelines do not advocate treatment with atypical antipsychotics unless a DSM-IV (American Psychiatric Association 1994) or ICD-10 (World Health Organization 1992) psychotic disorder is present, they endorse a time-limited therapeutic trial (6 months to 2 years, contingent on response within the initial 6 weeks) in the case of severe suicidality or where the treatment of depression has not been effective (Fig. 1). In addition, the guidelines support a similar approach for as much as 5 years after a first episode: i.e., that an atypical be tried for depression that does not respond to antidepressants or psychotherapy.

Although reduction of the duration of untreated psychosis and treatment of depression during the early phase of the illness is likely to be integral to addressing the risk of suicide (Upthegrove 2010), the literature on the efficacy or otherwise of pharmacological interventions for depression in schizophrenia in general, and in specific phases such as pretreatment, prodrome, acute or follow-up, is scarce and suffers from a number of fundamental problems, outlined in Box 3.

Given these general caveats, two major pharmacological issues need to be addressed. First, how effective are antidepressants in people with schizophrenia? And second, do the atypical antipsychotics have inherent antidepressant properties?

**Box 3** Methodological problems in assessing antidepressant effects in schizophrenia studies

- Low power: studies not ‘enriched’ for depression
- Severe depression or suicidality often an exclusion criterion
- Substance misuse often an exclusion criterion, leading to bias
- Reliance on measures of depression that are not optimal in people with schizophrenia
- Lack of appreciation of confounding effects of antipsychotic medications on factors such as sleep and appetite
- Lack of statistical control for secondary pathways such as alleviation of psychotic symptoms or extrapyramidal side-effects
The role of antidepressants

Regarding the use of antidepressants in schizophrenia, most of the (few) studies were only short term. In their review of the literature, Siris & Bench (2003) reported 13 randomised placebo-controlled trials where antidepressants were added to antipsychotics: all but 2 studies used tricyclic antidepressants (the 2 used sertraline). Of these 13 trials, only 4 were positive on the primary outcome measure: one of amitriptyline added to perphenazine (Prusoff 1979); one of imipramine to fluphenazine (with benztrpine) (Siris 1994); one of fluoxetine to a typical depot antipsychotic (Goff 1990); and one of sertraline to a ‘stable antipsychotic’ (Cooper 2000). In a Cochrane review (Furtado 2008), 11 randomised controlled trials (RCTs) were included, with a total of 470 patients. The authors pointed out the low number of participants in many trials and other design flaws, and concluded that ‘At present, there is no convincing evidence either to support or refute the use of antidepressants in treating depression in people with schizophrenia’.

An RCT which added flexibly dosed citalopram to antipsychotic medication for up to 12 weeks in middle-aged and older out-patients with schizophrenia found a reduction in suicidal ideation, when present at baseline, particularly in patients whose depressive symptoms were responsive to this treatment (Zisook 2010).

Longer-term studies are even thinner on the ground. Siris et al (1994) stabilised patients with comorbid schizophrenia and depression on a combination of fluphenazine (with benztrpine) and imipramine, then either withdrew the imipramine or continued it for a year. In patients in whom the antidepressant was continued, there were fewer depressive relapses. However, in a naturalistic study of patients with schizophrenia and broadly defined depression treated mostly with atypical antipsychotics and tricyclic antidepressants, Glick et al (2006) found that in 22 patients in whom the antidepressant was ceased, 18 experienced no significant mood change, 3 showed improvement in their depression, and in only 1 patient did the depression worsen. In a subsequent reflection on these and Siris et al’s data, Glick and colleagues (2008) stated, ‘We believe that for patients with chronic schizophrenia and moderate-to-severe depressive symptoms (and/or demoralisation) there may be some who might benefit from an antidepressant’; they give no guidance as to who ‘some’ might be.

Thus, it is fair to conclude that there are hardly grounds for a ringing endorsement of the use of antidepressants in people with schizophrenia, albeit that they remain widely used in clinical practice and it does seem that, as opined by Glick et al (2008), ‘some’ patients do benefit. Who those ‘some’ are is an open question, but most data are for full syndromal depression. One would also assume that antidepressants would be more likely to be indicated in more severe depression, and certainly in depression with melancholic features and/or suicidality.

Another factor is the potential for drug–drug interactions (e.g. fluvoxamine raises levels of clozapine dramatically, through its effect on the cytochrome P450 1A2 pathway) and exacerbation of side-effects of the prescribed antipsychotic. For example, selective serotonin reuptake inhibitors and selective noradrenaline reuptake inhibitors can have akathisia-like effects and are associated with sexual side-effects; and mirtazapine can cause somnolence and weight gain. In the light of this, one needs to consider the potential negative impact on medication adherence associated with polypharmacy.

Are atypical antipsychotics also antidepressants?

Many claims have been made for the superiority of atypical antipsychotics over the typical agents, including lower extrapyramidal side-effect burden, enhanced efficacy for negative symptoms, cognitive benefits and antidepressant efficacy. These factors are not mutually exclusive as, for example, a reduction in extrapyramidal side-effects would be expected to be associated with lower secondary negative symptom burden; and feeling less cognitively slowed could arguably enhance mood. Thus, any true test of whether atypical antipsychotics are antidepressive needs to accommodate these potential pathways: this has been done in only a few studies, as outlined below.

One could argue that demonstrable antidepressant effects of certain antipsychotics in bipolar depression and major depressive disorder would suggest that they would be beneficial for depression in schizophrenia. Notably, quetiapine (Calabrese 2005; Thase 2006; Suppes 2009) and olanzapine (Tohen 2003; Vieta 2010) have been successful for bipolar depression, while for major depressive disorder, quetiapine has been efficacious as a solo agent (Cutler 2009; McIntyre 2009; Weisler 2009) and as an adjunct to antidepressants (Dannlowski 2008), as has aripiprazole as an adjunct in major depressive disorder (Papakostas 2005; Patkar 2006; Rutherford 2007; Schwartz 2007; Arbaizaz 2009; Berman 2009; Steffens 2011) and bipolar disorder (Kemp 2007; Sokolski 2007; Arbaizaz 2009). But such assumptions might not be supportable, given the complexity
of schizophrenia, including its differential and multifactorial aetiology and epiphenomena. However, few methodologically robust studies have directly assessed the effects of atypical antipsychotics on depression in people with schizophrenia. This is in part because of the difficulties outlined in Box 3. Noting these caveats, Table 2 provides a synopsis of the main studies of atypical antipsychotics for depression in schizophrenia.

A recent review of data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) involving 1460 patients with chronic schizophrenia did not show any difference between atypical antipsychotics and the ‘typical’ comparator perphenazine, on depressive symptoms measured on the CDSS (Addington 2011). In other studies, it will be noted that the most consistent effects are seen for quetiapine and olanzapine. For olanzapine, the study of Tollefson and colleagues (1997) is particularly instructive, as it presents a path analysis suggesting that, after taking account of indirect mood effects such as amelioration of positive symptoms and extrapyramidal side-effects, 57% of the noted mood effects could be considered as a direct antidepressant effect.

**Table 2** Summary of atypical antidepressant efficacy for depression in schizophrenia

<table>
<thead>
<tr>
<th>Study (by first-named author)</th>
<th>Participants, n</th>
<th>Drug and study design</th>
<th>Duration</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kim (2007)</td>
<td>87</td>
<td>Amisulpride v. risperidone. Open label</td>
<td>12 weeks</td>
<td>Amisulpride: greater decrease in CDSS, PANSS depression, BDI</td>
</tr>
<tr>
<td>Kim (2010)</td>
<td>19</td>
<td>Aripiprazole switched to ziprasidone. Open label</td>
<td>12 weeks</td>
<td>Decrease in CDSS and BDI</td>
</tr>
<tr>
<td>Meltzer (1995)</td>
<td>321</td>
<td>Clozapine</td>
<td>3.5-year follow-up</td>
<td>Decrease in suicide attempts</td>
</tr>
<tr>
<td>Jasovic-Gasic (1997)</td>
<td>70</td>
<td>Clozapine v. unspecified antipsychotics plus mianserin or moclobemide, or placebo. RCT</td>
<td>4 weeks</td>
<td>Clozapine: greater decrease in HAMD</td>
</tr>
<tr>
<td>Walker (1997)</td>
<td>67,072</td>
<td>Clozapine. Data from national registry of users linked to national registers of deaths</td>
<td>2 years</td>
<td>Decrease in suicide in current v. past users</td>
</tr>
<tr>
<td>Meltzer (2003)</td>
<td>980</td>
<td>Clozapine v. olanzapine. RCT</td>
<td>2 years</td>
<td>Clozapine: decreased suicidal behaviour/Attempts</td>
</tr>
<tr>
<td>Mauri (2008)</td>
<td>222</td>
<td>Clozapine and quetiapine, and other antipsychotics (fluphenazine, haloperidol, olanzapine, risperidone, sulpiride). Observational study</td>
<td>12 weeks</td>
<td>Decreased BPRS depression for antipsychotics other than clozapine and quetiapine</td>
</tr>
<tr>
<td>Tollefson (1998)</td>
<td>335</td>
<td>Olanzapine v. haloperidol v. placebo. RCT</td>
<td>6 weeks</td>
<td>Olanzapine: greater decrease in BPRS score</td>
</tr>
<tr>
<td>Tran (1997)</td>
<td>339</td>
<td>Olanzapine v. risperidone. RCT</td>
<td>28 weeks</td>
<td>Olanzapine: greater decrease in PANSS depression and decrease in suicide attempts</td>
</tr>
<tr>
<td>Keck (1998)</td>
<td>139</td>
<td>Ziprasidone v. placebo. RCT</td>
<td>28 days</td>
<td>Decrease in BPRS depression</td>
</tr>
<tr>
<td>Daniel (1999)</td>
<td>312</td>
<td>Ziprasidone v. placebo. RCT</td>
<td>6 weeks</td>
<td>Decrease in BPRS depression</td>
</tr>
<tr>
<td>Dollfus (2005)</td>
<td>76</td>
<td>Olanzapine v. risperidone. RCT</td>
<td>8 weeks</td>
<td>Decrease in MADRS score</td>
</tr>
<tr>
<td>Tollefson (1997)</td>
<td>1996</td>
<td>Olanzapine v. haloperidol. RCT</td>
<td>6 weeks</td>
<td>Olanzapine: greater decrease in MADRS score</td>
</tr>
<tr>
<td>Ceskova (1993)</td>
<td>62</td>
<td>Risperidone v. haloperidol. RCT</td>
<td>8 weeks</td>
<td>Decrease in BPRS anxiety/depression</td>
</tr>
<tr>
<td>Möller (1995)</td>
<td>523</td>
<td>Risperidone v. haloperidol v. placebo. RCT</td>
<td>8 weeks</td>
<td>Decreased BPRS anxiety/depression</td>
</tr>
<tr>
<td>Peuskens (1995)</td>
<td>1362</td>
<td>Risperidone v. haloperidol. RCT</td>
<td>8 weeks</td>
<td>Decreased BPRS anxiety/depression</td>
</tr>
<tr>
<td>Emsley (2003)</td>
<td>269</td>
<td>Quetiapine v. haloperidol after non-response fluphenazine. RCT</td>
<td>8 weeks</td>
<td>Quetiapine: greater decrease in PANSS depression</td>
</tr>
<tr>
<td>Kasper (2004)</td>
<td>415</td>
<td>Quetiapine. Analysis of three RCTs, open-label phase</td>
<td>6 weeks</td>
<td>Decrease in BPRS anxiety/depression</td>
</tr>
<tr>
<td>Kopala (2006)</td>
<td>39</td>
<td>Quetiapine. Analysis of 2-year outcomes</td>
<td>2 years</td>
<td>improved PANSS and SDFAS scores</td>
</tr>
<tr>
<td>Lee (2008)</td>
<td>39</td>
<td>Quetiapine. Open label</td>
<td>6 weeks</td>
<td>Decrease in HAMD-17 and BPRS scores</td>
</tr>
<tr>
<td>Alfredsson (1984)</td>
<td>50</td>
<td>Sulpiride v. chlorpromazine. RCT</td>
<td>12 weeks</td>
<td>Decrease in CPRS</td>
</tr>
</tbody>
</table>

BDI, Beck Depression Inventory; BPRS, Brief Psychiatric Rating Scale; CDSS, Calgary Depression Scale for Schizophrenia; CPRS, Comprehensive Psychological Rating Scale; HAMD-17, 17-item Hamilton Depression Rating Scale; MADRS, Montgomery–Åsberg Depression Rating Scale; PANSS, Positive and Negative Syndrome Scale; RCT, randomised controlled trial; SDFAS, Social and Occupational Function Scale.
Another important finding from this literature is the antisuicide effect associated with clozapine. This has been shown in observational (Meltzer 1995) and case-register studies (Walker 1997) as well as in the landmark International Suicide Prevention Trial (InterSePT) comparing olanzapine with clozapine (Meltzer 2003). The precise mechanism whereby clozapine reduces suicidality is not fully understood, but presumably amelioration of depressed mood plays a part, and the data should sway clinicians in decisions about when to introduce clozapine in patients with schizophrenia at high risk for suicide.

A treatment framework
In his useful review, Siris (2000) suggests a pragmatic treatment framework for depression in schizophrenia (Fig. 2). For the treatment of established syndromal depression in people with schizophrenia, we suggest:

1. If symptoms still persist, consider antidepressant

2. address psychological and social issues, reinforcing the rehabilitation/recovery approach to treatment;
3. implement appropriate evidence-based psychological therapies;
4. consider using antipsychotics with established antidepressive properties;
5. if antidepressants are required, use those with lower propensity to side-effects and drug–drug interactions.

Conclusions
Depression is common in and often integral to schizophrenia throughout its course. In many ways this is understandable, given the nature of schizophrenia and the impact it has on the lives of individuals. In clinical practice, depression is often be overlooked because its symptoms and signs are mistaken for products of schizophrenia itself, or the right questions are not asked in the right way. It is incumbent upon clinicians to be alert to the possibility of depression in patients with schizophrenia (especially in the early phase of schizophrenia, when the potential to mitigate suicide risk is particularly high) and to manage it using a comprehensive biopsychosocial approach. In terms of medication, some atypical antipsychotics do seem to have primary antidepressant effects and this should inform clinical choice of agent in patients presenting with, or with a particular propensity towards, depression.

References
Advances in psychiatric treatment (2012), vol. 18, 280–288 doi: 10.1192/apt.bp.111.008961


Peuskens J, Moller HJ, Puech A (2002) Aripiprazole improves depressive symptoms in acute exacerbations of schizophrenia: comparison with...


MCQs
Select the single best option for each question stem

1 Depressive symptoms in people with schizophrenia:

a occur infrequently
b are easily separated from core symptoms of schizophrenia
c are rarely missed
d are adequately described by current classification systems (e.g. DSM and ICD)
e can cause significant distress and burden even when full syndromal criteria are not met.

2 With regard to schizoaffective disorder:

a there are broad diagnostic criteria in current classification systems
b the first operationalised diagnostic criteria were implemented at the time of the DSM-III in 1980
c this was originally described by Kraepelin
d a symptom-based therapeutic approach may be useful clinically

e DSM does not require a full affective syndrome for diagnosis.

3 With regard to treating depressive symptoms in schizophrenia with atypical antipsychotics:

a all atypicals are generally useful and similar in efficacy
b olanzapine and quetiapine have the least consistent effects
c clozapine has an antisuicide effect
d most studies are methodologically robust and have consistent comparators and outcome measures

e studies generally take into account the impact of extrapyramidal symptoms and cognitive functioning on mood.

4 In the pharmacological treatment of depression in schizophrenia, it is not helpful to:

a exclude organic or general medical factors
b explore stressors or prodromal symptoms
c increase the antipsychotic dose if depressive symptoms persist
d treat extrapyramidal side-effects
e consider augmentation with lithium or electroconvulsive therapy.

5 In treating established syndromal depression in schizophrenia, it may be helpful to:

a introduce antidepressant medication early, irrespective of positive and negative symptoms
b address psychological and social issues, with reinforcement of the rehabilitation/recovery approach
c use any antipsychotic medication, as all are similar in antidepressant properties
d use any psychological intervention, without the need for considering the evidence base
e use any antidepressant medication, as all are similar in side-effect profile and drug–drug interactions.